Cancer Chemother Pharmacol (2014) 73:35–42 DOI 10.1007/s00280-013-2314-7
Original Article
Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low‑volume multiple myeloma Sheeba K. Thomas · Alexander Suvorov · Lucien Noens · Oleg Rukavitsin · Joseph Fay · Ka Lung Wu · Todd M. Zimmerman · Helgi van de Velde · Rajesh Bandekar · Thomas A. Puchalski · Ming Qi · Clarissa Uhlar · Olga S. Samoylova Received: 15 May 2013 / Accepted: 3 October 2013 / Published online: 23 October 2013 © Springer-Verlag Berlin Heidelberg 2013
Abstract Purpose A phase 1 study evaluated the QTc prolongation potential of siltuximab, a chimeric, anti-interleukin-6 mAb, in patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), or low-volume MM. Methods Patients with baseline QTcF and QTcB ≤ 500 ms, QRS
Original Article
Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low‑volume multiple myeloma Sheeba K. Thomas · Alexander Suvorov · Lucien Noens · Oleg Rukavitsin · Joseph Fay · Ka Lung Wu · Todd M. Zimmerman · Helgi van de Velde · Rajesh Bandekar · Thomas A. Puchalski · Ming Qi · Clarissa Uhlar · Olga S. Samoylova Received: 15 May 2013 / Accepted: 3 October 2013 / Published online: 23 October 2013 © Springer-Verlag Berlin Heidelberg 2013
Abstract Purpose A phase 1 study evaluated the QTc prolongation potential of siltuximab, a chimeric, anti-interleukin-6 mAb, in patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), or low-volume MM. Methods Patients with baseline QTcF and QTcB ≤ 500 ms, QRS
